JPMorgan analyst Anupam Rama raised the firm’s price target on Vera Therapeutics to $72 from $62 and keeps an Overweight rating on the shares. The firm also the shares to its Analyst Focus List as a growth idea. The analyst sees a favorable setup for the stock, driven by the company’s lead asset atacicept in IgA Nephropathy and its “value creating catalysts” over the next 9-12 months. Should a win scenario play out in the 96-week Phase 2b data, the firm sees upside into $45-$50 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target lowered to $62 from $65 at JPMorgan
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics expects cash to fund operations through atacicept approval
- Vera Therapeutics reports Q2 EPS (62c), consensus (56c)
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results